行情

FENC

FENC

Fennec Pharms
NASDAQ

实时行情|Nasdaq Last Sale

6.10
-0.11
-1.77%
交易中 13:22 01/24 EST
开盘
6.22
昨收
6.21
最高
6.40
最低
6.10
成交量
5,634
成交额
--
52周最高
8.40
52周最低
3.255
市值
1.12亿
市盈率(TTM)
-9.9804
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FENC 新闻

  • 午盘:制造业PMI不及预期 美股下跌道指跌近100点
  • 新浪美股.1小时前
  • 数据显示Apple TV+四季度美国订阅用户达3360万
  • 新浪美股.1小时前
  • 迪斯尼+大获成功 大摩上调迪士尼目标价至170美元
  • 新浪美股.2小时前
  • 尚乘蔡志坚:数字化将进一步推动可持续发展
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
-2.17%
制药与医学研究
-1.62%

热门股票

名称
价格
涨跌幅

FENC 简况

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
展开

Webull提供Fennec Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。